BG Medicine, Inc. Announces Peer-Reviewed Publication on Galectin-3 and Development of Heart Failure After Acute Coronary Syndrome (ACS)

BG Medicine, Inc.

BG Medicine, Inc. Announces Peer-Reviewed Publication on Galectin-3 and Development of Heart Failure After Acute Coronary Syndrome (ACS)

November 30, 2011

WALTHAM, Mass., (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today the availability of the peer-reviewed publication of the first clinical study on the role of galectin-3 in heart failure development. Results of the pilot study, which consisted of a sub-study of patients from the Pravastatin or Atorvastin Evaluation and Infection Therapy — Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial, indicate that serum levels of galectin-3 are associated with increased risk of developing heart failure after suffering an acute coronary event, such as a heart attack. The study was conducted by the Boston-based TIMI Study Group at Brigham & Women's Hospital and Harvard Medical School. The results from the study were published in the November 22, 2011 online issue of the journal Clinical Chemistry, titled, "Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22," Grandin E, Jarolim P, Murphy S. DOI 10.1373/clinchem.2011.174359.

The study consisted of 100 patient cases from the PROVE IT-TIMI 22 trial, who had been hospitalized for new or worsening heart failure, which were analyzed against a matched set of control subjects. Serum levels of galectin-3 were measured within seven days following an acute coronary event using the BGM Galectin-3TM diagnostic test.

"Preclinical data suggested that galectin-3 may play an important role in the development of certain forms of heart failure. We designed this pilot study to investigate if elevated galectin-3 levels are indeed associated with an increased risk for heart failure development," said David A. Morrow, MD, MPH, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, and a Senior Investigator in the TIMI Study Group. "The results confirmed our hypothesis — that patients with levels of galectin-3 above the median were twice as likely to develop heart failure as those with lower levels of galectin-3."

"This is the second study this year to report on whether adverse health consequences are associated with elevated galectin-3 levels in patients without other signs or symptoms of heart failure. The first study (PREVEND) demonstrated, in the general population, that elevated galectin-3 levels are associated with an increased risk of cardiovascular-related death. The TIMI 22 galectin-3 sub-study suggests that elevated galectin-3 levels also increase the risk for the development of heart failure," said Pieter Muntendam, MD, President and CEO of BG Medicine. "These findings are consistent with the suggestions drawn from previously reported animal data. The same animal data suggest that inhibition of galectin-3 may slow down or stop this process and potentially prevent the development of heart failure."

About Galectin-3 and Heart Failure

Galectin-3 is a unique carbohydrate-binding lectin, or protein, that binds to carbohydrates called beta-galactosides. Galectin-3 has been implicated in a variety of biological processes important in the development and progression of heart failure, and is believed to be a primary mediator of progressive cardiac fibrosis (abnormal thickening and stiffening of the heart muscle) and adverse remodeling (changes in the structure of the heart). Higher levels of galectin-3 are associated with a more aggressive form of heart failure and 30% or more of mild to moderate heart failure patients will have elevated levels of galectin-3. Heart failure affects an estimated 5.8 million Americans, with approximately 670,000 new cases occurring each year. The direct and indirect cost of heart failure in the United States for 2010 is estimated to be $39.2 billion.

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD) is a life sciences company focused on the discovery, development, and commercialization of novel, biomarker-based diagnostics to improve patient outcomes and contain healthcare costs. The Company recently launched the BGM Galectin-3TM test for use in patients with heart failure, the first novel blood test for cardiac disease cleared by the U.S. F.D.A. in five years. BG Medicine also has products in development to aid in the diagnosis and management of acute atherothrombosis and lipid disorders. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.

The BG Medicine Inc. logo is available at: http://www.globenewswire.com/newsroom/prs/?pkgid=8765

Special Note Regarding Forward-looking Statements

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. Forward-looking statements in this news release address our expectations concerning the role that galectin-3 plays in the development of heart failure, our beliefs regarding the importance of the galectin-3 data presented in the publication Clinical Chemistry, and our expectations regarding the impact of the galectin-3 data on the sales and marketing of our galectin-3 diagnostic tests. Forward-looking statements are based on management's current expectations and involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our recent filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
 

CONTACT:

Michael W. Rogers

EVP & Chief Financial Officer

(781) 890-1199